Accession Number: | 0001367644-21-000041 |
Date: | 2021-02-24 |
Issuer: | EMERGENT BIOSOLUTIONS INC. (EBS) |
Original Submission Date: |
LINDAHL RICHARD S
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG, MD 20879
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-02-24 | A | 4,011 | a | $0.00 | 35,790 | direct | ||
COMMON STOCK | 2021-02-24 | A | 4,012 | a | $0.00 | 39,802 | direct | ||
COMMON STOCK | 2021-02-24 | F | 1,010 | d | $93.49 | 38,792 | direct | ||
COMMON STOCK | 2021-02-26 | F | 819 | d | $97.15 | 37,973 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTIONS (RIGHT TO BUY) | 93.49 | 2021-02-24 | deemed execution date | A | 16,043 (a) | 2028-02-23 | common stock 16,043 | $93.49 | 16,043 | direct |
ID | footnote |
---|---|
f1 | consists of restricted stock units granted under the company's stock incentive plan. these restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. each restricted stock unit represents the right of the reporting person to receive one share of common stock of emergent biosolutions inc., subject to adjustment as provided in the grant agreement. |
f2 | consists of performance stock units granted under the emergent biosolutions inc. stock incentive plan. each psu represents a right to receive one share of common stock. the psus vest upon achievement with respect to adjusted ebitda margin calculated on a cumulative basis over the three-year period beginning january 1, 2021 and ending december 31, 2023, as certified by the compensation committee following the performance period. the amount reported is based on the target performance payout factor, or 100%. |
f3 | represents shares of common stock withheld to pay taxes. |
f4 | vests in three equal installments beginning on the day prior to the anniversary date of the grant. |